Clovis Oncology, Inc. CLVS Stock
Clovis Oncology, Inc. Price Chart
Clovis Oncology, Inc. CLVS Financial and Trading Overview
Clovis Oncology, Inc. stock price | 0.08 USD |
Previous Close | 0.08 USD |
Open | 0.08 USD |
Bid | 0 USD x 800 |
Ask | 0 USD x 1200 |
Day's Range | 0.08 - 0.1 USD |
52 Week Range | 0.04 - 3.25 USD |
Volume | 24.21M USD |
Avg. Volume | 5.97M USD |
Market Cap | 11.77M USD |
Beta (5Y Monthly) | 0.220545 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 2 USD |
CLVS Valuation Measures
Enterprise Value | 634.07M USD |
Trailing P/E | N/A |
Forward P/E | -0.09783133 |
PEG Ratio (5 yr expected) | 0 |
Price/Sales (ttm) | 0.08848555 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 4.767 |
Enterprise Value/EBITDA | -3.191 |
Trading Information
Clovis Oncology, Inc. Stock Price History
Beta (5Y Monthly) | 0.220545 |
52-Week Change | -98.18% |
S&P500 52-Week Change | -5.39% |
52 Week High | 3.25 USD |
52 Week Low | 0.04 USD |
50-Day Moving Average | 0.41 USD |
200-Day Moving Average | 1.22 USD |
CLVS Share Statistics
Avg. Volume (3 month) | 5.97M USD |
Avg. Daily Volume (10-Days) | 8.29M USD |
Shares Outstanding | 144.96M |
Float | 142.86M |
Short Ratio | 4.63 |
% Held by Insiders | 1.43% |
% Held by Institutions | 25.89% |
Shares Short | 28.49M |
Short % of Float | 20.03% |
Short % of Shares Outstanding | 19.65% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2021 |
Most Recent Quarter (mrq) | September 30, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -189.37% |
Operating Margin (ttm) | -155.15% |
Gross Margin | 76.24% |
EBITDA Margin | -149.35% |
Management Effectiveness
Return on Assets (ttm) | -30.18% |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 133.02M USD |
Revenue Per Share (ttm) | 0.96 USD |
Quarterly Revenue Growth (yoy) | -19.10% |
Gross Profit (ttm) | 115.3M USD |
EBITDA | -198676000 USD |
Net Income Avi to Common (ttm) | -251906000 USD |
Diluted EPS (ttm) | -2.084 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 58.32M USD |
Total Cash Per Share (mrq) | 0.4 USD |
Total Debt (mrq) | 680.62M USD |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 0.137 |
Book Value Per Share (mrq) | -2.886 |
Cash Flow Statement
Operating Cash Flow (ttm) | -175575008 USD |
Levered Free Cash Flow (ttm) | -128193376 USD |
Profile of Clovis Oncology, Inc.
Country | United States |
State | CO |
City | Boulder |
Address | 5500 Flatiron Parkway |
ZIP | 80301 |
Phone | 303 625 5000 |
Website | https://www.clovisoncology.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 413 |
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. On December 11, 2022, Clovis Oncology, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Q&A For Clovis Oncology, Inc. Stock
What is a current CLVS stock price?
Clovis Oncology, Inc. CLVS stock price today per share is 0.08 USD.
How to purchase Clovis Oncology, Inc. stock?
You can buy CLVS shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Clovis Oncology, Inc.?
The stock symbol or ticker of Clovis Oncology, Inc. is CLVS.
Which industry does the Clovis Oncology, Inc. company belong to?
The Clovis Oncology, Inc. industry is Biotechnology.
How many shares does Clovis Oncology, Inc. have in circulation?
The max supply of Clovis Oncology, Inc. shares is 129.98M.
What is Clovis Oncology, Inc. Price to Earnings Ratio (PE Ratio)?
Clovis Oncology, Inc. PE Ratio is 0.00000000 now.
What was Clovis Oncology, Inc. earnings per share over the trailing 12 months (TTM)?
Clovis Oncology, Inc. EPS is 0 USD over the trailing 12 months.
Which sector does the Clovis Oncology, Inc. company belong to?
The Clovis Oncology, Inc. sector is Healthcare.
Clovis Oncology, Inc. CLVS included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
Dow Jones U.S. Biotechnology In DJUSBT | 2713.11 USD — |
-2.04
|
67.04M USD — | 2703.19 USD — | 2755.25 USD — | — - | 67.04M USD — |
NASDAQ Biotechnology Total Retu XNBI | 4501.69 USD — |
-2.14
|
— — | 4479.13 USD — | 4578.05 USD — | — - | — — |
NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
NASDAQ Composite Total Return I XCMP | 19659.36 USD — |
-1.62
|
— — | 19598.88 USD — | 19861.56 USD — | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}